Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model
- PMID: 26997019
- PMCID: PMC4822375
- DOI: 10.4103/0971-5916.178615
Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model
Abstract
Background & objectives: Methicillin resistant Staphylococcus aureus (MRSA) are the commonest cause of osteomyelitis. The aim of this study was to evaluate the role of an alternative therapy i.e. application of S. aureus specific bacteriophages in cases of osteomyelitis caused by MRSA in animal model.
Methods: Twenty two rabbits were included in this study. The first two rabbits were used to test the safety of phage cocktail while the remaining 20 rabbits were divided into three groups; group A (n=4) to assess the establishment of osteomyelitis; group B (n=4) osteomyelitis developed but therapy started only after six weeks; and group C (n=12) osteomyelitis developed and therapy started after three weeks. Groups B and C rabbits were treated with four doses of cocktail of seven virulent bacteriophages at the interval of 48 h. Comparison between three groups was made on the basis of observation of clinical, radiological, microbiological, and histopathological examinations.
Results: Experimental group rabbits recovered from the illness in the subsequent two weeks of the therapy. Appetite and activity of the rabbits improved, local oedema, erythema and induration subsided. There were minimal changes associated with osteomyelitis in X-ray and histopathology also showed no signs of infection with new bone formation. Control B group rabbits also recovered well from the infection.
Interpretation & conclusions: The present study shows a potential of phage therapy to treat difficult infections caused by multidrug resistant bacteria.
Conflict of interest statement
Figures




Comment in
-
Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model.Front Microbiol. 2016 Aug 10;7:1251. doi: 10.3389/fmicb.2016.01251. eCollection 2016. Front Microbiol. 2016. PMID: 27558214 Free PMC article. No abstract available.
-
A need for careful consideration of bacteriophage therapy.Indian J Med Res. 2016 Sep;144(3):482-483. doi: 10.4103/0971-5916.198691. Indian J Med Res. 2016. PMID: 28139548 Free PMC article. No abstract available.
References
-
- Lew DP, Waldvogel FA. Osteomyelitis. Lancet. 2004;364:369–79. - PubMed
-
- Brady RA, Leid JG, Calhoun JH, Costerton JW, Shirtliff ME. Osteomyelitis and the role of biofilms in chronic infection. FEMS Immunol Med Microbiol. 2008;52:13–22. - PubMed
-
- Lazzarini L, de Lalla F, Mader JT. Long bone osteomyelitis. Curr Infect Dis Rep. 2002;4:439–45. - PubMed
-
- Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials? Int J Infect Dis. 2005;9:127–38. - PubMed
MeSH terms
Supplementary concepts
LinkOut - more resources
Full Text Sources